{"id":"alx1-11-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALX1-11 binds to and neutralizes Wnt ligands, which are secreted signaling molecules involved in developmental and regenerative processes. By blocking Wnt signaling, the drug aims to reduce pathological cell growth and proliferation in conditions where this pathway is dysregulated. This mechanism is particularly relevant in oncology and certain genetic disorders characterized by excessive Wnt pathway activation.","oneSentence":"ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:08.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wnt-driven cancers (investigational)"}]},"trialDetails":[{"nctId":"NCT00172172","phase":"PHASE3","title":"Calcium Supplementation in Postmenopausal Women","status":"COMPLETED","sponsor":"Shire","startDate":"2004-01-10","conditions":"Osteoporosis","enrollment":374},{"nctId":"NCT00172133","phase":"PHASE3","title":"Open Label Extension Study of PREOS","status":"COMPLETED","sponsor":"Shire","startDate":"2001-10-16","conditions":"Osteoporosis","enrollment":1683},{"nctId":"NCT00172120","phase":"PHASE3","title":"Open Label Extension","status":"COMPLETED","sponsor":"Shire","startDate":"2005-01-10","conditions":"Osteoporosis","enrollment":91},{"nctId":"NCT00172107","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Shire","startDate":"1995-05-18","conditions":"Osteoporosis","enrollment":217},{"nctId":"NCT00172081","phase":"PHASE3","title":"TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Shire","startDate":"2000-04-27","conditions":"Osteoporosis","enrollment":2532}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PREOS"],"phase":"phase_3","status":"active","brandName":"ALX1-11 (drug)","genericName":"ALX1-11 (drug)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation. Used for Wnt-driven cancers (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}